201 related articles for article (PubMed ID: 18675436)
1. APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages.
Miyagi E; Schwartzkopff F; Plishka R; Buckler-White A; Clouse KA; Strebel K
Virology; 2008 Sep; 379(2):266-74. PubMed ID: 18675436
[TBL] [Abstract][Full Text] [Related]
2. Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.
Kao S; Goila-Gaur R; Miyagi E; Khan MA; Opi S; Takeuchi H; Strebel K
Virology; 2007 Dec; 369(2):329-39. PubMed ID: 17825339
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.
Goila-Gaur R; Khan MA; Miyagi E; Kao S; Opi S; Takeuchi H; Strebel K
Virology; 2008 Mar; 372(1):136-46. PubMed ID: 18023836
[TBL] [Abstract][Full Text] [Related]
4. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
Miyagi E; Opi S; Takeuchi H; Khan M; Goila-Gaur R; Kao S; Strebel K
J Virol; 2007 Dec; 81(24):13346-53. PubMed ID: 17928335
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
Opi S; Kao S; Goila-Gaur R; Khan MA; Miyagi E; Takeuchi H; Strebel K
J Virol; 2007 Aug; 81(15):8236-46. PubMed ID: 17522211
[TBL] [Abstract][Full Text] [Related]
6. Insights into the dual activity of SIVmac239 Vif against human and African green monkey APOBEC3G.
Gaur R; Strebel K
PLoS One; 2012; 7(11):e48850. PubMed ID: 23189135
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
8. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
[TBL] [Abstract][Full Text] [Related]
9. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
10. The Disassociation of A3G-Related HIV-1 cDNA G-to-A Hypermutation to Viral Infectivity.
Martin J; Chen X; Jia X; Shao Q; Liu B
Viruses; 2024 May; 16(5):. PubMed ID: 38793610
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
12. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.
Miller JH; Presnyak V; Smith HC
Retrovirology; 2007 Nov; 4():81. PubMed ID: 18036235
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
15. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
Stopak K; de Noronha C; Yonemoto W; Greene WC
Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
[TBL] [Abstract][Full Text] [Related]
17. The viral infectivity factor (Vif) of HIV-1 unveiled.
Rose KM; Marin M; Kozak SL; Kabat D
Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.
Mandal D; Exline CM; Feng Z; Stoltzfus CM
J Virol; 2009 Jun; 83(12):6067-78. PubMed ID: 19357165
[TBL] [Abstract][Full Text] [Related]
19. DNAJB8 facilitates autophagic-lysosomal degradation of viral Vif protein and restricts HIV-1 virion infectivity by rescuing APOBEC3G expression in host cells.
Chand K; Barman MK; Ghosh P; Mitra D
FASEB J; 2023 Mar; 37(3):e22793. PubMed ID: 36723955
[TBL] [Abstract][Full Text] [Related]
20. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.
Donahue JP; Vetter ML; Mukhtar NA; D'Aquila RT
Virology; 2008 Jul; 377(1):49-53. PubMed ID: 18499212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
